Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

Bullboard Posts
Comment by joelouon Oct 14, 2018 1:14pm
71 Views
Post# 28797417

RE:RE:RE:RE:US LISTING

RE:RE:RE:RE:US LISTINGAlthough I’ve used ONC in my example of possible share consolidation scenarios, I don’t think it’s an apples to apples situation here with DMA.   I really like DMA because they have shown( fingers crossed) that what they have replaces another drug already on the market  as well as possible other indications where this drug could be applicable too.   What I was hoping is that we would see positive results out of  Australia before they  proceed with the share consolidation...  One thing for sure, is that the stock may become very illiquid after the consolidation and that may hurt (or help- depending on results) the share price like we are seeing with ONC as they wait on news.   One other thing, I thought this Chinese licensing deal would have propelled  the stock much higher than what the  share price is currently sitting at —  and my thought is that management thought the same as well...  interesting times that’s for sure!!!
 Cheers. JL
Bullboard Posts